Cytogen, Inc. (KOSDAQ: A217330)
Health Care · Biotechnology · KR
₩3,155.00
-12.12% today · +17.1% 1Y
Cytogen, Inc. (KOSDAQ: A217330) operates in the Biotechnology industry within the Health Care sector. The company is valued at $52.52M.
Over the last twelve months the share price has gained 17.1%, trading between 2.26K and 11.20K.
Tweenvest scores Cytogen, Inc. across four factors: quality 35/100, value 59/100. Its strongest factor is value.
A217330 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $52.52M
- Revenue (TTM)
- $17.68M
- P/E
- —
- EPS
- -456.83
- Dividend yield
- —
- Beta (5Y)
- 0.25
- 52-week high
- ₩11,200.00
- 52-week low
- ₩2,260.00
- Avg volume (3M)
- —
- Shares outstanding
- 23.07M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.